Updating the ATS/ERS Task Force Report on Outcomes for COPD Pharmacological Trials.
Mario CazzolaPaola RoglianiPeter J BarnesFrancesco BlasiBartolome R CelliNicola A HananiaFernando J MartinezBruce E MillerMarc MiravitllesClive P PageRuth Tal-SingerMaria Gabriella MateraPublished in: American journal of respiratory and critical care medicine (2023)
Since the 'label-free' treatable traits approach is becoming an important step toward precision medicine, future clinical trials should focus on highly prevalent treatable traits, which will influence the choice of outcomes and markers to be considered. The use of the new tools, particularly combination endpoints, could help identify better the right patient to be treated with the new drugs.